Sydney’s EnGeneIC Raises Funds in Singapore for Targeted Nanocell Technology

Australia’s EnGeneIC, a company developing a targeted nanocell technology for cancer therapies, announced financial partnerships with two Singapore entities, Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI). Although the investment amount was not disclosed, the financing was called “significant.” The funding will be used to advance EnGeneIC’s proprietary technology, EnGeneIC Dream Vector, for oncology and infectious diseases. The first-in-class EDVTM nanocell is the basis of an antibody nanocell drug conjugate platform for delivering therapeutic payloads -- drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting of a cancer cell’s surface with minimal toxicity. More details....

Share this with colleagues: